The preterm birth prevention and management market size is expected to grow from USD 1.91 billion in 2025 to USD 2.08 billion in 2026 and is forecast to reach USD 3.17 billion by 2031 at 8.83% CAGR over 2026-2031. This report is Segmented by Intervention (Therapeutics, Diagnostics), Route of Administration (Vaginal, Oral, Parenteral), End User (Hospitals, Maternity & Fertility Clinics, and More), Gestational-Age Risk Category (Extremely Preterm, Very Preterm, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).
Diagnostics are posting the fastest 9.41% CAGR, fuelled by fibronectin kits, PAMG-1 assays, and cervical-length ultrasound systems that integrate with machine-learning risk-scoring. High negative predictive value shortens hospital stays and guides targeted steroid use, strengthening payer backing. Combined, these trends reinforce the preterm birth prevention and management market as a prevention-first clinical environment.
Vaginal delivery captured 44.02% share of the preterm birth prevention and management market size in 2025 because local dosing concentrates progesterone where it is needed and minimizes systemic side effects. Self-administration, sustained-release rings, and low storage costs favour further adoption.
Oral formulations are accelerating at 9.62% CAGR, energised by micronization and protective coatings that lift bioavailability to therapeutic thresholds. Patients prefer tablets for convenience, and physicians value simplified prescribing. Parenteral routes retain a corner niche for emergency tocolysis but face user discomfort and higher site-of-care costs.
Asia-Pacific registers the quickest 10.05% CAGR, propelled by broader insurance coverage, government device-approval reforms, and multi-country cohort studies such as CARE-Preterm that standardise neonatal care. China’s expanding NICU network and India’s Single Window regulatory portal are shortening product-rollout timelines, while Japan is integrating vaginal progesterone into routine obstetrics. Collectively, the region is reshaping volume dynamics for the preterm birth prevention and management market.
Europe, the Middle East and Africa, and South America offer incremental upside. EMA’s suspension of 17-hydroxyprogesterone caproate is accelerating adoption of alternative agents. Sub-Saharan Africa remains the highest-incidence region yet faces infrastructure gaps, creating white-space for low-cost diagnostics and telehealth. South American regulators are investing in maternal-health capacity building, helping lift baseline demand.
Global Preterm Birth Prevention And Management Market Trends and Insights
Escalating Global Incidence of Preterm Births
Preterm births now affect 13.4 million infants a year, anchoring steady demand across therapeutic and diagnostic segments. Rising maternal age, multiple-birth pregnancies from assisted-reproductive technologies, and persistent care disparities sustain the upward trend. Low- and middle-income countries shoulder the heaviest burden, yet cost pressures are global because life-long care of survivors tops USD 30 billion in annual spending in the United States alone. This epidemiology is driving simultaneous growth in preventive interventions and neonatal intensive-care technologies, reinforcing a dual-growth dynamic that keeps the preterm birth prevention and management market expanding on multiple fronts.Clinical-Guideline Shift Toward Progesterone Therapy
Professional societies now endorse vaginal progesterone for women with short cervix after the withdrawal of 17-hydroxyprogesterone caproate. The pivotal PREGNANT trial showed a 45% drop in preterm deliveries, eliminating earlier uncertainty and unifying prescribing patterns. Pharmaceutical firms are responding with sustained-release microcrystal formulations that improve adherence, while genetic research is clarifying which patients benefit most. The resulting clarity is channelling capital toward route-of-administration innovation and supports predictable volume growth.FDA Withdrawal of Makena and Tighter Regulations
Regulators pulled 17-hydroxyprogesterone caproate from the market in 2023 after efficacy and safety doubts surfaced, forcing clinicians to redesign treatment protocols and raising evidentiary hurdles for new agents. The action lengthens development timelines and raises capital requirements for future therapeutics, tempering growth momentum in the near term even as it safeguards patient outcomes.Other drivers and restraints analyzed in the detailed report include:
- Rapid Uptake of Point-of-Care Biomarker Tests
- Government Maternal-Health Funding Boosts
- Limited Novel-Drug R&D Investment
Segment Analysis
Therapeutics retained leadership with a 60.62% slice of the preterm birth prevention and management market in 2025, anchored by progesterone, calcium channel blockers, and corticosteroids. Vaginal progesterone remains first line, while nifedipine outperforms historic tocolytics in prolonging gestation. Corticosteroids continue to support fetal lung maturation under strict gestational-age windows. Pipeline activity spans oxytocin-receptor antagonists and vasodilator combinations, yet uptake hinges on clearer survival data.Diagnostics are posting the fastest 9.41% CAGR, fuelled by fibronectin kits, PAMG-1 assays, and cervical-length ultrasound systems that integrate with machine-learning risk-scoring. High negative predictive value shortens hospital stays and guides targeted steroid use, strengthening payer backing. Combined, these trends reinforce the preterm birth prevention and management market as a prevention-first clinical environment.
Vaginal delivery captured 44.02% share of the preterm birth prevention and management market size in 2025 because local dosing concentrates progesterone where it is needed and minimizes systemic side effects. Self-administration, sustained-release rings, and low storage costs favour further adoption.
Oral formulations are accelerating at 9.62% CAGR, energised by micronization and protective coatings that lift bioavailability to therapeutic thresholds. Patients prefer tablets for convenience, and physicians value simplified prescribing. Parenteral routes retain a corner niche for emergency tocolysis but face user discomfort and higher site-of-care costs.
Complete Report Scope:
- By Intervention
- Therapeutics
- Calcium Channel Blockers
- Progesterone Therapy
- Oxytocin Receptor Antagonists
- Corticosteroids
- Others
- Diagnostics
- Biomarker Test Kits (fFN, PAMG-1)
- Cervical Length Ultrasound Devices
- Other Diagnostic Tools
- Therapeutics
- By Route of Administration
- Vaginal
- Oral
- Parenteral
- By End User
- Hospitals
- Maternity & Fertility Clinics
- Home Healthcare Settings
- Research & Academic Institutes
- By Gestational-Age Risk Category
- Extremely Preterm (< 28 w)
- Very Preterm (28-32 w)
- Moderate-Late Preterm (32-37 w)
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- North America
Geography Analysis
North America commanded 41.76% of the preterm birth prevention and management market share in 2025, sustained by reimbursement structures, NIH funding streams, and guideline maturity. Market penetration of rapid biomarker tests and sustained-release progesterone is already high. Regulatory uncertainty after Makena’s withdrawal spurred tighter pharmacovigilance but also nudged clinics toward diagnostically driven care paths.Asia-Pacific registers the quickest 10.05% CAGR, propelled by broader insurance coverage, government device-approval reforms, and multi-country cohort studies such as CARE-Preterm that standardise neonatal care. China’s expanding NICU network and India’s Single Window regulatory portal are shortening product-rollout timelines, while Japan is integrating vaginal progesterone into routine obstetrics. Collectively, the region is reshaping volume dynamics for the preterm birth prevention and management market.
Europe, the Middle East and Africa, and South America offer incremental upside. EMA’s suspension of 17-hydroxyprogesterone caproate is accelerating adoption of alternative agents. Sub-Saharan Africa remains the highest-incidence region yet faces infrastructure gaps, creating white-space for low-cost diagnostics and telehealth. South American regulators are investing in maternal-health capacity building, helping lift baseline demand.
List of Companies Covered in this Report:
- Ferring Pharmaceuticals
- Hologic
- The Cooper Companies
- Covis Pharma
- Besins Healthcare
- Pfizer
- Merck
- Cipla
- Sun Pharmaceuticals Industries
- Dr. Reddy’s Laboratories
- Lupin
- ObsEva SA
- Cook Group
- QIAGEN
- Utah Medical Products
- MedGyn Products
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts (Value)
6 Competitive Landscape
7 Market Opportunities & Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Ferring Pharmaceuticals
- Hologic Inc.
- CooperSurgical Inc.
- Covis Pharma
- Besins Healthcare
- Pfizer Inc.
- Merck KGaA
- Cipla Ltd.
- Sun Pharma
- Dr. Reddy’s Laboratories
- Lupin Pharma
- ObsEva SA
- Cook Medical
- QIAGEN
- Utah Medical Products Inc.
- MedGyn Products Inc.
